Peter Kjeld Slotwiner-Nie
Michele C. Siciliano
Dr. Siciliano's clinical focus is on the care of patients who require urgent or emergent general surgical operations as well as critically ill patients in the Intensive Care unit.
<p>Michele C. Siciliano, MD, is an acute care surgeon at Montefiore Einstein. She specializes in the care of patients who require urgent or emergent general surgical operations as well as critically ill patients in the Intensive Care unit. She also provides elective general surgical care.</p><p>After receiving her Bachelor of Science in Kinesiology: Athletic Training from the University of New Hampshire in 2003, Dr. Siciliano spent five years between undergraduate and medical schools working as an Athletic Trainer and Medical Assistant. She then attended the Sackler School of Medicine in Tel Aviv, Israel, from 2008 to 2012, earning her Doctor of Medicine. She completed her postdoctoral training with a residency in general surgery at Maine Medical Center in 2018, followed by a fellowship in surgical critical care at Duke University Medical Center in 2019. She then returned to New York, and spent two and a half years working as a Trauma and Acute Care Surgeon for New York City Health and Hospitals: Harlem Hospital prior to joining Montefiore Einstein.</p><p>Dr. Siciliano is board certified by the American Board of Surgery in General Surgery and Surgical Critical Care. She is a Fellow of the American College of Surgeons and is a member of the Eastern Association for the Surgery of Trauma as well as the Society of Critical Care Medicine.</p>
Mark Shlomovich
Albumin Dialysis
Care of children before and after solid organ transplantation
<p>Mark Shlomovich, MD, is Director, Extracorporeal Liver Support and Director, Pediatric Critical Care Transport at Children’s Hospital at Montefiore and Assistant Professor, Pediatrics at Montefiore-Einstein. Dr. Shlomovich’s clinical focus is on the care of critically ill children with abdominal organ failure, transplantation and post-surgical care. He also focuses on the safe transportation of critically ill children.</p><p>In 2006, Dr. Shlomovich earned his Bachelor of Science in biology from Towson University. He then attended University of Connecticut School of Medicine earning his Doctor of Medicine in 2010. His postgraduate training began at SUNY Downstate Medical Center with a four-year pediatric residency, where he was Chief Pediatric Resident in his final year. He then came to Children's Hospital at Montefiore for a pediatric critical care fellowship, which he completed in 2017.</p><p>Dr. Shlomovich’s research interests are in the use of artificial liver support technology, as well as the care of children in liver failure before and after transplantation. In addition, he investigates the safety and efficiency of the transportation of critically ill children. He has shared his research through peer-reviewed journals and abstracts, and is an ad hoc reviewer for BMC Nephrology.</p><p>Dr. Shlomovich is board certified in general pediatrics and pediatric critical care medicine. He is a member of the Society of Critical Care Medicine and the American Academy of Pediatrics.</p>
Howard I. Sherman
Colon cancer screening<quillbot-extension-portal></quillbot-extension-portal>
Colon cancer screening<quillbot-extension-portal></quillbot-extension-portal>
<p>Howard I. Sherman, MD, is an attending physician and Adjunct Associate Clinical Professor, Gastroenterology at Montefiore Einstein. His clinical focus centers on colon cancer screening.</p><p>After earning his Doctor of Medicine at Einstein in 1973, Dr. Sherman began his postdoctoral training at Emory University. There, he completed his medical internship in 1974, his internal medicine residency in 1976 and a digestive diseases fellowship in 1978.</p><p>Building on his clinical focus, Dr. Sherman’s research is focused on colon cancer screening.</p><p>Dr. Sherman is board certified in Gastroenterology and is a Diplomat of the National Board of Medical Examiners and the American Board of Internal Medicine. He is a member of several professional organizations, including the American Gastroenterology Association, the American College of Gastroenterology, the American Society for Gastrointestinal Endoscopy and the American Association for the Study of Liver Disease.</p>
Jonathan M. Schwartz
<p>Jonathan M. Schwartz is a board Certified Transplant Hepatologist. He is a graduate of Tel Aviv University, Sackler School of Medicine. He was an Internal Medicine Resident at Albert Einstein College of Medicine and a Fellow in Gastroenterology/Transplant Hepatology at the University of Washington in Seattle. He returned to New York in 2011 from Portland, Oregon where he served as an Associate Professor of Medicine at Oregon Health and Sciences University.</p>
<p>Dr. Schwartz has an interest in treating patients with acute and chronic liver diseases including those patients with advanced liver diseases who require liver transplantation.</p>
<p>He has a special interest in the multidisciplinary care of patients with liver tumors.</p>
<p><strong><br /></strong></p>
<ul>
<li>Estes JD, Stolpman D, Olyaei A, Ham JM, <strong>Schwartz JM</strong>, Orloff SL. High Prevalence of Potentially Hepatotoxic Herbal Supplement Use in Fulminant Hepatic Failure Patients. Arch Surg. 2003;138(8):852-8.</li>
<li><strong>Schwartz JM</strong>, Beymer C, Althaus SJ, Larson AM, Zaman A, Glickerman D, Kowdley KV. Cardiopulmonary Consequences of Transjugular Intrahepatic Portosystemic Shunts: Role of Increased Pulmonary Artery Pressure. J Clin Gastroenterol 2004;38(7):590-594.</li>
<li>Lim LL, Scarborough J, Thorne J, Graham E, Kempen J, Mackensen F, Nguyen Q D, Prabriputaloong T, Read R, Suhler EB, <strong>Schwartz JM</strong>, Smith JR. Uveitis in Patients with Autoimmune Hepatitis. Am J Ophthalmol. 2009;147(2):332-338.</li>
<li>O’Glasser AY, Scott DA, Corless CL, Zaman A, Sasaki A, Gopal DV, Rayhill SC, Orloff SL, Ham JM, Rabkin JM, Flora K, Davies CH, Broberg CS, and <strong>Schwartz JM.</strong>Hepatic and Cardiac Iron Overload Among Patients with End-Stage Liver Disease Referred for Liver Transplantation. Clinical Transplantation. Clin Transplant. 2010 Sep-Oct;24(5):643-51.</li>
<li>Kanwal F, Befeler A, Chari R, Marrero J, Kahn J, Afdhal N, Morgan T, Roberts L, Mohanty SR, <strong>Schwartz J</strong>, Van Thiel D, Hassanein TI, Li J, Zeringue A, DiBisceglie A. Rate of Potentially Curative Treatment in Patients with Hepatocellular Carcinoma. Aliment Pharmacol Ther. 2012 Aug;36(3):257-65.</li>
<li>Bichoupan K1, <strong>Schwartz JM,</strong> Martel-Laferriere V, Giannattasio ER, Marfo K, Odin JA, Liu LU, Schiano TD, Perumalswami P, Bansal M, Gaglio PJ, Kalia H,Dieterich DT, Branch AD, Reinus JF. Effect of Fibrosis on Adverse Events in Patients with Hepatitis C Treated with Telaprevir. Aliment Pharmacol Ther. 2014;39(2):209-16.</li>
<li><strong>Schwartz J</strong> and Carithers RL. Epidemiology and Etiologic Associations of Primary Hepatocellular Carcinoma. In Rose BD, editor. Up to date in Gastroenterology and Hepatology. Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li><strong>Schwartz JM </strong>and Carithers RL, Jr. Clinical features, diagnosis, and screening for primary hepatocellular carcinoma. Up to date in Gastroenterology and Hepatology. Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li>Curley SA, Stewart KE, <strong>Schwartz JM</strong>, Carthers RL, Jr. Nonsurgical therapies for localized hepatocellular carcinoma. Up to date, Inc. Wellesley, MA, Updated 2014.<strong> </strong></li>
<li><strong>Schwartz JM</strong>. Approach to the patient with a focal liver lesion. Up to date Inc Gastroenterology and Hepatology. Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li>Hartwell L and <strong>Schwartz JM. </strong>AsymptomaticLiver Chemistry Abnormalities. Journal of Clinical Outcomes Management. 2009; 16 (11): 525-34.</li>
<li>Urquhart J<strong>, Schwartz, JM.</strong> Hepatocellular Carcinoma Surveillance in a Western Population with Hepatitis B. Current Hepatitis Reports, 2011.</li>
<li><strong>Schwartz, JM </strong>and Reinus JF. Prevalence and Natural History of Alcoholic Liver Disease. Clinics in Liver Disease. 2012; 16 (4): 659-66.</li>
</ul>
<p> </p>
Orna Rosen
Samuel J. Rednor
Nephrology and Critical Care.
Dr. Rednor’s research focus is in acute kidney injury (AKI), cardiac arrest, and intubation.
<p>Samuel J. Rednor, DO, is Director of Wellness, Critical Care and Assistant Professor, Medicine at Montefiore Einstein. His clinical focus is nephrology and critical care.</p><p>After earning his Doctor of Osteopathic Medicine at Lake Erie College of Osteopathic Medicine in 2013, Dr. Rednor completed his residency in internal medicine at Southampton Hospital in 2016, where he was Chief Resident for one year. He then completed his renal fellowship at Montefiore in 2018, where he was Chief Renal Fellow during his last year. Dr. Rednor went on to complete an additional fellowship at Montefiore in critical care, which he completed in 2019.</p><p>Dr. Rednor’s research focus is in acute kidney injury (AKI), cardiac arrest, and intubation. His work has been published in peer-reviewed journals and he has given multiple lectures and presentations.</p><p>Dr. Rednor is board certified in Internal Medicine, Nephrology and Critical Care Medicine by the American Osteopathic Board of Internal Medicine. He is a member of the American Society of Nephrology (ASN), the American Osteopathic Association (AOA), the Society of Critical Care Medicine (SCCM) and the American College of Chest Physicians (CHEST). In 2018, Dr. Rednor won the Sharon R. Silbiger Teaching Award for excellence in teaching and in recognition as Outstanding Fellow of the Year from Einstein.</p>